Kurt A. Stoeckli

President and Chief Scientific Officer at Glenmark Pharmaceuticals Limited

Location:
Glenmark House B D S Marg Chakala Off Western Express Highway, Mumbai, Maharashtra, India
Company:
Glenmark Pharmaceuticals Limited
HQ Phone:
+91 22 4018 9999
Wrong Kurt Stoeckli?

Last Updated 11/30/2017

General Information

Employment History

Scientific Director  - Vitry-Alfortville

Global Head of Lead Discovery Technologies  - Aventis SA

Lab Head  - Core Technologies

Education

ETH Zürich

University of Basel

Ph.D.  - 

Affiliations

Vice President Global Research and Development, Head  - Sanofi-Aventis SA

Scientific Advisory Board Member  - Aurora Biomed Inc

Postdoctoral Fellow and Assistant Professor In the Department of Biochemistry and Biophysics  - University of California

Vice President Member of the Global Discovery Board and Head of Lead Identification Technologies Sanofi-Aventis Sciences and Medical Affairs, Germany  - MipTec

Research Programme Head  - Novartis AG

Web References  

Executive Team | Glenmark

Dr. Kurt Stoeckli
Kurt Stoeckli Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and branded formulations research. Dr. Stoeckli brings more than 25 years of experience in the global life sciences industry where he focused on biopharmaceutical research and development. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation in Germany, and most recently as Group Vice President for the Global Biotherapeutics Division, in Paris. Dr. Stoeckli first joined industry in 1993 with Novartis in Basel, Switzerland where he held increasing leadership positions and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his Ph.D. in Molecular Cell Biology. Dr. Stoeckli is a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.

Read More
http://www.glenmarkpharma.com/about-us/executive-team

Dr. Kurt Stoeckli
Kurt Stoeckli Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and branded formulations research. Dr. Stoeckli brings more than 25 years of experience in the global life sciences industry where he focused on biopharmaceutical research and development. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation in Germany, and most recently as Group Vice President for the Global Biotherapeutics Division, in Paris. Dr. Stoeckli first joined industry in 1993 with Novartis in Basel, Switzerland where he held increasing leadership positions and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his Ph.D. in Molecular Cell Biology. Dr. Stoeckli is a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.

Read More
Kurt Stoeckli, PhD

Kurt Stoeckli, PhD
President and Chief Scientific Officer Glenmark Pharmaceuticals Ltd Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and branded formulations research. Dr. Stoeckli brings more than 25 years of experience in the global life sciences industry where he focused on biopharmaceutical research and development. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation, and most recently as Group Vice President for the Global Biotherapeutics Division, based in Paris. Dr. Stoeckli first joined industry in 1993 with Novartis in Basel, Switzerland where he held positions of increasing leadership and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his PhD in Molecular Cell Biology. Dr. Stoeckli has been a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.

Read More

Browse ZoomInfo’s Directories